Lazard Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Lazard Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-923	Closed	-$22K	–	1827
2019 Q4	$22K	Buy	923 +834	+937%	+$23K	﹤0.01%	1214
2019 Q3	$2K	Buy	+89	New	+$2.5K	﹤0.01%	1422
2018 Q1	–	Sell	-6,586	Closed	-$320K	–	1159
2017 Q4	$320K	Buy	+6,586	New	+$333K	﹤0.01%	833
2016 Q4	–	Sell	-122,300	Closed	-$2.78M	–	1081
2016 Q3	$2.78M	Sell	122,300 -169,463	-58%	-$3.98M	0.01%	594
2016 Q2	$6.88M	Buy	291,763 +155,863	+115%	+$3.85M	0.01%	461
2016 Q1	$2.77M	Buy	+135,900	New	+$4.31M	0.01%	572

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Lazard Asset Management's PTLA Position: Q1 2020 in Review

Lazard Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 923 shares — an estimated $22K sold.

Lazard Asset Management first reported a position in PTLA in Q1 2016 and held it in 6 quarters. The position peaked at $6.88M in Q2 2016. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Lazard Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Lazard Asset Management sold 923 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $22K.
Lazard Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2016 and held it in 6 quarters.
Lazard Asset Management's Portola Pharmaceuticals, Inc. position peaked at $6.88M in Q2 2016.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Lazard Asset Management's 13F filing for Q1 2020, filed 14 May 2020.